A Phase 4 interventional study of Pegloticase and Methotrexate in Gout, sponsored by Amgen. Completed at 74 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.
Among the 14 studies testing pegloticase in Gout, this one has the largest enrollment, is the only one that started in 2024, is one of 7 in phase 4, and was the 13th registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 306 is above the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 93 across the 14 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 9 studies filed under Gout — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing pegloticase in Gout, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout.
The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to \< 6 mg/dL for at least 80% of the time.
Acquired from Horizon in 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Uncontrolled gout, defined as meeting the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
16 mg pegloticase will be administered intravenously every 4 weeks for 24 weeks during double blind treatment and 24 weeks during open label.
Biological: Pegloticase · Drug: Methotrexate
8 mg pegloticase will be administered intravenously every 2 weeks for 24 weeks during double blind treatment and 16 mg pegloticase every 4 weeks for 24 weeks during open label.
Biological: Pegloticase · Drug: Methotrexate
IV infusion
Also known as: Krystexxa
Oral
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Responders were defined as participants who achieved and maintained sUA levels below 6 mg/dL for at least 80% of the time during Month 6. Responders who met sUA discontinuation criteria (2 consecutive sUA \> 6 mg/dL), regardless of treatment status were considered non-responders.
Time frame: Month 6 (Weeks 20, 21, 22, 23, and 24)
Percentage of Participants With Complete Resolution of ≥ 1 Tophus at Week 24 in Participants With Tophi at Baseline
Time frame: Baseline, Week 24
Participants were enrolled at 51 trial centers in United States of America from 18 March 2024. The primary analysis data is presented for the double-blind period up to 30 July 2025, with a database snapshot date of 26 September 2025; the trial is ongoing, and data from the open-label period will be posted with the final analysis. A 4 week methotrexate (MTX) run in period with weekly dose of 15 mg was used to identify screening failures due to MTX intolerance.
| Milestone | MTX Run-In Period: All Participants | Pegloticase 8mg Q2W + MTX | Pegloticase 16mg Q4W + MTX |
|---|---|---|---|
| Started | 306 | 0 | 0 |
| Completed | 262 | 0 | 0 |
| Not completed | 44 | 0 | 0 |
| Withdrew: Unable to tolerate mtx | 9 | 0 | 0 |
| Withdrew: Inclusion criteria not met | 19 | 0 | 0 |
| Withdrew: Exclusion criteria met | 11 | 0 | 0 |
| Withdrew: Inclusion criteria not met and exclusion criteria met | 1 | 0 | 0 |
| Withdrew: Various reasons | 4 | 0 | 0 |
| Milestone | MTX Run-In Period: All Participants | Pegloticase 8mg Q2W + MTX | Pegloticase 16mg Q4W + MTX |
|---|---|---|---|
| Started | 0 | 130 | 131 |
| Received at least 1 dose of pegloticase | 0 | 130 | 131 |
| Completed | 0 | 113 | 113 |
| Not completed | 0 | 17 | 18 |
| Withdrew: Lost to follow-up | 0 | 2 | 2 |
| Withdrew: Participant decision | 0 | 15 | 16 |
Responders were defined as participants who achieved and maintained sUA levels below 6 mg/dL for at least 80% of the time during Month 6. Responders who met sUA discontinuation criteria (2 consecutive sUA \> 6 mg/dL), regardless of treatment status were considered non-responders.
| percentage of participants | Pegloticase 8mg Q2W + MTX | Pegloticase 16mg Q4W + MTX |
|---|---|---|
| Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 | 70.8 (62.2 to 78.4) | 56.5 (47.6 to 65.1) |
Results for this outcome have not been posted.
Collected over For all-cause mortality: from signing of inform consent form (ICF) through database lock (DBL) for primary analysis (up to Week 24); For Serious adverse events and other adverse events: from first dose of MXT through DBL for the primary analysis (up to Week 24).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MTX Run-In Period: All Participants | 0/306 (0%) | 2/306 (0.7%) | 61/306 (19.9%) |
| Pegloticase 8mg Q2W + MTX | 0/130 (0%) | 4/130 (3.1%) | 66/130 (50.8%) |
| Pegloticase 16mg Q4W + MTX | 0/131 (0%) | 9/131 (6.9%) | 87/131 (66.4%) |
| Event | MTX Run-In Period: All Participants | Pegloticase 8mg Q2W + MTX | Pegloticase 16mg Q4W + MTX |
|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 0/306 | 1/130 | 3/131 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 0/306 | 1/130 | 0/131 |
| Obstructive pancreatitisGastrointestinal disorders | 0/306 | 1/130 | 0/131 |
| PyelonephritisInfections and infestations | 0/306 | 1/130 | 0/131 |
| Atrial fibrillationCardiac disorders | 0/306 | 0/130 | 1/131 |
| Cardiac failure congestiveCardiac disorders | 1/306 | 0/130 | 1/131 |
| Herpes zosterInfections and infestations | 0/306 | 0/130 | 1/131 |
| PneumoniaInfections and infestations | 0/306 | 0/130 | 1/131 |
| Pneumonia influenzalInfections and infestations | 0/306 | 0/130 | 1/131 |
| Orthostatic hypotensionVascular disorders | 0/306 | 0/130 | 1/131 |
| Event | MTX Run-In Period: All Participants | Pegloticase 8mg Q2W + MTX | Pegloticase 16mg Q4W + MTX |
|---|---|---|---|
| GoutMetabolism and nutrition disorders | 61/306 | 62/130 | 81/131 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/306 | 10/130 | 3/131 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/306 | 9/130 | 9/131 |
The Full analysis set (FAS) included all participants who received at least 1 dose of pegloticase.
| Age, Continuous(years) | Pegloticase 8mg Q2W + MTX | Pegloticase 16mg Q4W + MTX | Total |
|---|---|---|---|
| Mean | 56.4 ± 10.6 | 53.2 ± 11.6 | 54.8 ± 11.2 |
| Sex: Female, Male(Participants) | Pegloticase 8mg Q2W + MTX | Pegloticase 16mg Q4W + MTX | Total |
|---|---|---|---|
| Female | 7 | 6 | 13 |
| Male | 123 | 125 | 248 |
| Ethnicity (NIH/OMB)(Participants) | Pegloticase 8mg Q2W + MTX | Pegloticase 16mg Q4W + MTX | Total |
|---|---|---|---|
| Hispanic or Latino | 58 | 55 | 113 |
| Not Hispanic or Latino | 67 | 70 | 137 |
| Unknown or Not Reported | 5 | 6 | 11 |
| Race/Ethnicity, Customized(Participants) | Pegloticase 8mg Q2W + MTX | Pegloticase 16mg Q4W + MTX | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 6 | 8 | 14 |
| Black or African American | 30 | 20 | 50 |
| Multiple | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 91 | 100 | 191 |
| Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · amgen.com
Ran from Mar 2024 to primary completion in Jul 2025, 16 months.
Results were first posted in Jul 2026, 11 months after primary completion.
Of 18 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pegloticase · Methotrexate